Sobi launches website to help people with haemophilia live without compromise
Sobi, the biopharmaceutical company focused on rare diseases, has launched a new UK website called Liberate Life for people with haemophilia.
The Swedish-headquartered multinational, which has offices at Granta Park, says the site will provide support, resources and the latest information for those with the condition to encourage them to live a life without compromise.
Neil Dugdale, vice-president and general manager for Sobi UK & RoI, says: “As part of Sobi’s commitment to people with haemophilia, we aim to shape new standards, optimise treatment, build evidence and create sustainable care access.
“Liberate Life is an initiative which looks at the bigger picture, focusing on providing valuable support and improving individual’s quality of life as a whole. We are proud to provide this continued support, challenging the status quo in Haemophilia care.”
Sobi’s commitment follows a large-scale European ethnographic study that showed people with haemophilia are living with fear and therefore missing out on a good quality of life.
The new website encourages individuals to “live beyond their condition” by sharing real life stories from ‘liberators’ within the haemophilia community.
It offers tailored support to parents, teenagers and seniors and helps visitors to understand haemophilia.
Features include advice on caring for a child with haemophilia and discussion of work, travel and lifestyle choices, frequently asked questions, details on treatment and tips for maintaining good joint health.
Sobi is working with The Haemophilia Society to develop content and resources for the website and Facebook community.
Liz Carroll, chief executive of The Haemophilia Society, said: “Haemophilia doesn’t just impact the individual living with the condition. Working in collaboration with Sobi, and with the help of the community, we are producing helpful and informative resources to support, encourage and motivate people with haemophilia to seek more from life and hope to inspire individuals, driving positive change.”
A rare genetic disorder in which the ability of the blood to clot is impaired, there are two main forms of haemophilia.
Haemophilia A affects around 6,752 people while haemophilia B affects about 1,494 individuals in the UK.
The main aim of treatment is to prevent bleeding and protect against complications. The type of treatment depends upon the severity of the bleeding disorder severity.
While there is no cure, it can be managed so individuals lead full, healthy and active lives.
Visit https://liberatelife.co.uk/.
Read more
Healx signs deal with Boehringer Ingelheim to aid fight against rare neurological diseases
